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We have identified a mammalian arginine N-methyl-
transferase, PRMT7, that can catalyze the formation of
-NG-monomethylarginine in peptides. This protein is
encoded by a gene on human chromosome 16q22.1 (hu-
man locus AK001502). We expressed a full-length human
cDNA construct in Escherichia coli as a glutathione S-
transferase (GST) fusion protein. We found that GST-
tagged PRMT7 catalyzes the S-adenosyl-[methyl-3H]-L-
methionine-dependent methylation of the synthetic
peptide GGPGGRGGPGG-NH2 (R1). The radiolabeled
peptide was purified by high-pressure liquid chroma-
tography and acid hydrolyzed to free amino acids. When
the hydrolyzed products were separated by high-resolu-
tion cation-exchange chromatography, we were able to
detect one tritiated species which co-migrated with an
-NG-monomethylarginine standard. Surprisingly, GST-
PRMT7 was not able to catalyze the in vitro methylation
of a GST-fibrillarin (amino acids 1–148) fusion protein
(GST-GAR), a methyl-accepting substrate for the previ-
ously characterized PRMT1, PRMT3, PRMT4, PRMT5,
and PRMT6 enzymes. Nor was it able to methylate mye-
lin basic protein or histone H2A, in vitro substrates of
PRMT5. This specificity distinguishes PRMT7 from all of
the other known arginine methyltransferases. An addi-
tional unique feature of PRMT7 is that it seems to have
arisen from a gene duplication event and contains two
putative AdoMet-binding motifs. To see if both motifs
were necessary for activity, each putative domain was
expressed as a GST-fusion and tested for activity with
peptides R1 and R2 (acetyl-GGRGG-NH2). These trun-
cated proteins were enzymatically inactive, suggesting
that both domains are required for functionality.
Protein arginine methylation is an apparently irreversible
modification in which the guanidinium group of arginyl resi-
dues becomes methylated in a reaction with S-adenosylmethi-
onine (AdoMet).1 This modification has been implicated in the
regulation of signal transduction (1–4), transcription (5–7),
RNA transport (8), and RNA splicing (9). Four different types of
protein arginine methyltransferases have been described. Type
I enzymes catalyze the formation of -NG-monomethylarginine
and -NG,NG-asymmetric dimethylarginine residues. Type II
enzymes form -NG-monomethylarginine and -NG,NG’-sym-
metric dimethylarginine residues. Type III enzymes catalyze
only the formation of -NG-monomethylarginine residues. Fi-
nally, type IV enzymes form -NG-monomethylarginine (for a
review, see Ref. 10). The previously described mammalian en-
zymes PRMT1, PRMT3, PRMT4/CARM1, and PRMT6 and the
yeast enzyme RMT1 have been shown to be responsible for type
I methylation (5, 11–14). The mammalian enzyme PRMT5/
JBP1 catalyzes type II methylation (15), whereas the yeast
RMT2 enzyme catalyzes type IV methylation (16). No activity
has currently been defined for the mammalian PRMT2 gene
product, although its amino acid sequence is similar to that of
the other PRMT gene products (17).
In searching the human genome for novel protein arginine
methyltransferases, we found a gene that appears to code for
the seventh PRMT. A recombinantly expressed form of this
PRMT is incapable of methylating GST-GAR, MBP, and his-
tone H2A, typical substrates of the previously described protein
arginine methyltransferases. However, this methyltransferase,
now designated PRMT7, is able to methylate two arginine-
containing peptides and exhibited type III enzymatic activity,
catalyzing the formation of -NG-monomethylarginine resi-
dues. A similar species has recently been described in Chinese
hamster cells, but the biochemical reaction catalyzed by it has
not yet been determined (18).
EXPERIMENTAL PROCEDURES
Construction of PRMT7, PRMT7C, and PRMT7N Expression Vec-
tors—The plasmid pGEX-PRMT7 was constructed by PCR amplifica-
tion of a 2.1-kb fragment from a template of an IMAGE human cDNA
clone (clone ID 2900965; GenBank accession number AW675040) with
primers PRMT7-N1 (5-CTA GTG TCG ACC ATG AAG ATC TTC TGC
AGT CGG GCC-3) and PRMT7-C1 (5-CT CGC GGC CGC TCA GTC
TTG GGT ATC TGC ATG CCT GAA CTC-3). The PCR fragment was
digested with SalI and NotI and ligated into pGEX(SN) (19). The
plasmid pGEX-PRMT7C was constructed by PCR-amplifying from
pGEX-PRMT7 a 1.1-kb fragment with primers PRMT7-N1 and PRMT7-
C1 (5-CTC TCC TCA CCG CGG CCG CTT CAA GAG CAG GTG AGC
CTG-3), which introduces a single N375K mutation to place a NotI site
at the 3 end of the fragment for the purpose of cloning. The PCR
product was digested with SalI and NotI and ligated into pGEX(SN).
The plasmid pGEX-PRMT7N was constructed by PCR amplification of
pGEX-PRMT7 with primers PRMT7-N1 (5-CTA GTG TCG ACC ATG
TTT GGA GAG ATC AAT GAC CAG-3) and PRMT7-C1, resulting in a
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950-bp fragment. PCR fragments were digested with SalI and NotI and
ligated into pGEX(SN).
Purification of GST-GAR, GST-PRMT1, GST-PRMT7, GST-
PRMT7C, and GST-PRMT7N—GST-GAR and GST-PRMT1 were
constructed as described previously (11, 13). GST-GAR, GST-PRMT1,
GST-PRMT7, GST-PRMT7C, and PRMT7N were overexpressed in
Escherichia coli DH5 cells (Invitrogen) by induction with 0.4 mM
isopropyl--D-thiogalactopyranoside. Cells were lysed in the presence of
100 M phenylmethylsulfonyl fluoride with seven 20-s sonicator pulses
(50% duty; setting 4) on ice with a Sonifier cell disrupter W-350 (Smith-
Kline Corp.). The resulting lysate was centrifuged for 40 min at
23,000  g at 4 °C. The protein was then purified from extracts by
binding to glutathione-Sepharose 4B beads (Amersham Biosciences)
according to the manufacturer’s instructions; the GST-fusion proteins
were eluted with 30 mM glutathione, 50 mM Tris-HCl, pH 7.5, and 120
mM NaCl at protein concentrations of 0.1 to 0.2 mg/ml.
In Vitro Labeling of MBP, Histone H2A, GST-GAR, Peptide R1, and
Peptide R2 and Chemical Analysis of the Methylated Species—10 g of
myelin basic protein (MBP) (purified from bovine brain, lyophilized
powder; Sigma), 10 g of histone H2A (purified from calf thymus, Roche
Applied Science), 10 g GST-GAR, 52 g peptide R1 (GGPGGRGGPG-
NH2, California Peptide Research, Inc.) or 26.5 g of peptide R2 (acetyl-
GGRGG-NH2, California Peptide Research, Inc.) was incubated with 2
g of GST-PRMT7. 52 g of peptide R1 or 26.5 g of peptide R2 were
FIG. 1. Amino acid sequence alignment of the N-terminal region of human PRMT7 with other known human protein arginine
methyltransferases. The catalytic core regions common to all known human PRMT family members are shown. Amino acids (black boxes) match
a majority consensus. Signature seven -strand methyltransferase motifs I, post I, II, and III are boxed. The PRMT-conserved glutamate residues
of the “double E” loop are indicated by asterisks, and the PRMT-conserved THW loop is also boxed. (The PRMT1 splice variant 2 is shown in this
alignment.)
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incubated with 2 g of PRMT7C or PRMT7N. Sodium phosphate
buffer (pH 7.5) was added to all reactions to a final concentration of 100
mM. Reactions were initiated by the addition of 3 l of S-adenosyl-L-
[methyl-3H]methionine ([3H]AdoMet, Amersham Pharmacia Biotech;
72.0–79.0 Ci/mmol; 13–14 M) in a final volume of 60 l. Reactions were
allowed to proceed at 37 °C for 1 h. As a control, 2 g of GST-GAR was
added to 2 g of GST-PRMT1 and sodium phosphate buffer (pH 7.5) for
a final concentration of 100 mM and incubated at 37 °C for 30 min with
3 l of [3H]AdoMet in a final volume of 30 l. Reactions were stopped by
freezing on dry ice. The in vitro reactions for MBP, histone H2A, and
GST-GAR were mixed with 20 g of bovine serum albumin as a carrier
protein and an equal volume of 25% (w/v) trichloroacetic acid in a 6 
50-mm glass vial and incubated at room temperature for 30 min. The
precipitated protein was then centrifuged at 4000  g for 30 min at
25 °C, the supernatant was drawn off and discarded, and the pellets
were allowed to air dry. Acid hydrolysis was then carried out on these
reactions in a water Pico-Tag Vapor-Phase apparatus in vacuo for 20 h
at 110 °C using 200 l of 6 N HCl. The in vitro reactions for peptides R1
and R2 were added to a 6  50-mm glass vial and dried by speed
vacuum. 50 l of 6 N HCl was added to each vial, and the samples were
hydrolyzed in vacuo for 20 h at 110 °C.
Hydrolyzed samples were resuspended in 50 l of water and mixed
with 1.0 mol of each of the standard -NG-monomethylarginine (-
MMA, acetate salt, Sigma) and asymmetric -NG,NG-dimethylarginine
(ADMA, hydrochloride, Sigma) for amino acid analysis by column chro-
matography. 500 l of citrate dilution buffer (0.2 M Na, pH 2.2) was
added to the hydrolyzed samples before loading onto a cation-exchange
column (Beckman AA-15 sulfonated polystyrene beads; 0.9-cm inner
diameter  7-cm column height) equilibrated and eluted with sodium
citrate buffer (0.35 M Na, pH 5.27) at 1 ml/min at 55 °C.
Analysis of Column Fractions—Amino acid standards were deter-
mined by a ninhydrin assay as described previously (13). Radioactivity
in column fractions was quantitated using a Beckman LS6500 counter
as an average of three 3-min counting cycles. The efficiency of counting
was determined to be 36% using a calibrated standard.
High-pressure Liquid Chromatography (HPLC) Purification of Meth-
ylated Peptide R1 and Chemical Analysis of the Purified Methylated
Product—520 g of peptide R1 was added to 20 g of GST-PRMT7 and
incubated with 10 l of [3H]AdoMet at 37 °C for 5 h in a final volume of
600 l and a final concentration of 100 mM sodium phosphate. All
reactions were stopped by freezing on dry ice. Samples were then
thawed and dried under vacuum in a Speed Vac apparatus and resus-
pended in 60 l of water. An equal volume of 10% trifluoroacetic acid
was added to acidify the reaction and precipitate out the proteins that
were present. The sample was spun at 10,000  g for 5 min, and the
supernatant was injected onto a C18 reverse-phase column (5-micron
spherical particles, column dimensions 4.6  250 mm; Alltech Econo-
sphere) equilibrated at room temperature in solvent A (0.1% trifluoro-
acetic acid in water). At a flow rate of 1 ml/min, the sample was eluted
with increasing proportions of solvent B (0.1% trifluoroacetic acid, 0.9%
water in acetonitrile) using the following gradient: 0–5 min, 0% B; 5–55
min, 0–100% B; 55–65 min, 100% B; and 65–70 min, 100–0% B. The
column effluent was monitored at 214 nm and 1-ml fractions were
collected. Fractions corresponding to the peptide peak were pooled and
concentrated under vacuum to 200 l. Samples were reinjected onto
the C18 column and eluted under the same conditions as before. Frac-
tions corresponding to the peptide peak were dried under vacuum in a
6  50-mm glass vial. 50 l of 6 N HCl was added to each 6  50-mm
glass vial, and acid hydrolysis was then carried out on the reactions in
a water Pico-Tag Vapor-Phase apparatus in vacuo for 20 h at 110 °C.
The hydrolyzed samples were resuspended in 50 l of water and ana-
lyzed on a cation exchange column as described above.
UV Crosslinking with [3H]AdoMet—Either 7.2 g of GST-PRMT7,
3.2 g of GST-PRMT7C, or 2 g of GST-PRMT7N were incubated
with 0.8 M [3H]AdoMet (72 Ci/mmol) and 5 mM dithiothreitol in 50 mM
sodium phosphate, pH 7.4, in a total volume of 50 l. In control reac-
FIG. 2. Purification of GST-PRMT7 and crosslinking to
[3H]AdoMet. A, Coomassie Blue-stained SDS gel of purified GST-
PRMT7 (2 g of protein) and molecular mass standards (Bio-Rad:
phosphorylase, 97.4 kDa; serum albumin, 66.2 kDa; ovalbumin, 42.7
kDa; carbonic anhydrase, 31 kDa; and soybean trypsin inhibitor, 21.5
kDa). B, GST-PRMT7 (7.2 g of protein) was incubated with
[3H]AdoMet in the absence or presence of AdoMet, AdoHcy, MTA, or
ATP, as indicated, and irradiated at 254 nm. Polypeptides were sepa-
rated on an SDS-polyacrylamide gel and analyzed by fluorography, as
described under “Experimental Procedures” with a 39-day exposure
time. The migration position of GST-PRMT7 is shown by an asterisk in
A and B.
FIG. 3. GST-PRMT7 is incapable of methylating GST-GAR, my-
elin basic protein, or histone H2A. Substrates were incubated with
[3H]AdoMet and enzyme, and the reaction mixture was precipitated
with trichloroacetic acid, acid-hydrolyzed, and analyzed by amino acid
analysis, as described under “Experimental Procedures.” 3H-radioactiv-
ity (, Œ) was determined by counting a 200-l aliquot of every other
fraction diluted with 400 l of water in 5 ml of fluor (Safety Solve,
Research Products International) three times for 3 min. Unlabeled
amino acid standards (ADMA and -MMA) were analyzed using a
ninhydrin assay with 100-l aliquots of every other fraction (solid
lines). A, analysis of GST-GAR labeled in vitro with either GST-PRMT7
() or GST-PRMT1 (Œ). 3H-radioactivity values for GST-PRMT1 are
divided by 100. B, analysis of MBP labeled with GST-PRMT7. C, anal-
ysis of histone H2A labeled with GST-PRMT7.
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tions, unlabelled AdoMet (HSO4
 salt, Roche Molecular Biochemicals),
S-adenosyl-L-homocysteine (AdoHcy, Sigma), 5-deoxy-5-methyl-thio-
adenosine (MTA, Sigma) or ATP (Sigma) were added to a final concen-
tration of 100 M. Samples were added to 96-well plates and incubated
at 4 °C for 20 mins. Samples were exposed to UV irradiation at 254 nm
using a Model UVGL-25 Mineralight lamp (UVP, Inc., San Gabriel, CA)
held directly against the 96-well plate. The reaction was stopped by the
addition of 50 l of SDS gel sample buffer (180 mM Tris/HCl, pH 6.8, 4%
SDS, 0.1% aˆ-mercaptoethanol, 20% glycerol, and 0.002% bromphenol
blue) and heating at 100 °C for 5 min. Samples were electrophoresed at
35 mA for 4 h using a Laemmli buffer system on a gel prepared with
10% acrylamide and 0.34% N,N-methylene-bisacrylamide (1.5-mm
thick, 10.5 cm resolving gel, 2 cm stacking gel). Gels were stained with
Coomassie Brilliant Blue R-250 for 30 min and destained in 10% meth-
anol and 5% acetic acid overnight. For fluorography, gels were treated
with EN3HANCE (PerkinElmer Life Sciences). Gels were dried at 70 °C
in vacuo and exposed to Kodak X-Omat AR scientific imaging film at
80 °C.
RESULTS AND DISCUSSION
The PRMT family of enzymes exhibits amino acid conserva-
tion within the characteristic seven -strand methyltrans-
ferase motifs I, post I, II, and III (20), and in other portions of
the polypeptide chain (14, 21). A search of the GenBank NR
amino acid database using the gapped-BLAST method (22) for
sequences that match known PRMT enzymes identified a full-
length cDNA as part of the National Institutes of Health Mam-
malian Gene Collection (23). This cDNA (locus AK001502) is
encoded by a gene on human chromosome 16q22.1 and itself
encodes a 692-amino acid hypothetical protein FLJ10640. We
compare the sequence of this protein, now designated PRMT7,
with the six previously described human PRMTs in Fig. 1.
PRMT7, although sharing conserved seven -strand methyl-
transferase motifs I and post I with other PRMTs, appears
more distantly related at motifs II and III. Significantly,
PRMT7 shares additional sequences common to only the PRMT
family in the N-terminal region (residues 22–65) in the region
between motifs I and post I and at two active-site regions, the
“double E” loop and adjacent sequences between motifs II and
III, and the THW loop and adjacent sequences at residues
312–330 (21, 24). Interestingly, although the two glutamate
residues are present at the conserved positions in the double E
loop, there is only marginal similarity in the residues in be-
tween that are generally conserved in most of the other PRMT
enzymes. Furthermore, PRMT7 is unique among these en-
zymes in that the threonine residue of the THW loop is replaced
by an aspartic acid residue in PRMT7.
A protein-protein BLAST search of the GenBank NR data-
base with the human PRMT7 sequence revealed clear orthologs
in a variety of organisms including mice (85% identity over 690
residues), the frog Xenopus laevis (64% identity over 686 resi-
dues), the fly Drosophila melanogaster (36% identity over 706
residues), the worm Caenorhabditis elegans (30% identity over
700 residues), and the higher plant Arabidopsis thaliana (31%
identity over 667 residues). However, we find no homologs in
the yeasts Saccharomyces cerevisiae and Schizosaccharomyces
pombe or in prokaryotes.
A plasmid encoding a fusion construct of GST and the full-
length coding sequence of PRMT7 was expressed in E. coli cells
and purified by affinity chromatography, as described under
“Experimental Procedures.” A single major polypeptide of 108
kDa was observed, consistent with that expected for GST
linked to the 692-residue PRMT7 polypeptide (Fig. 2A). We
first asked if the GST-PRMT7 fusion protein could bind to the
methyl donor AdoMet. GST-PRMT7 was exposed to UV irradi-
ation at 254 nm in the presence of [3H]AdoMet. The reaction
mixture was then fractionated by SDS gel electrophoresis and
analyzed by fluorography. As shown in Fig. 2B, a radiolabeled
band was observed migrating at 108 kDa, corresponding to the
GST-PRMT7 fusion polypeptide. In control experiments, addi-
tion of the non-isotopically labeled AdoMet and AdoHcy sub-
strate and product fully inhibited the crosslinking reaction,
whereas the addition of the UV-absorbing non-substrate ATP
had no effect. An intermediate effect was seen with the sub-
strate analog MTA (Fig. 2B).
Histones, MBP, and GST-GAR have been used as methyl-
accepting substrates to identify, partially purify, and charac-
terize protein-arginine N-methyltransferases (12, 15, 25). To
identify the possible methyltransferase activity of PRMT7, the
GST-fusion protein was incubated with GST-GAR, MBP, or
histone H2A in the presence of [3H]AdoMet. Protein reaction
products were precipitated with trichloroacetic acid, acid-hy-
drolyzed to their amino acid components, and fractionated by
high-resolution amino acid cation-exchange chromatography
along with standards of unlabeled asymmetric ADMA and
-MMA (Fig. 3). No protein arginine methyltransferase activ-
ity was observed when GST-GAR, MBP, or histone H2A was
used as a substrate for GST-PRMT7. However, activity was
seen in a control experiment when GST-GAR was used as a
substrate for GST-PRMT1 under these conditions (Fig. 3A).
Because PRMT7 cannot use these substrates as methyl-accep-
tors, PRMT7 may have a substrate specificity that is distinct
from the other known arginine methyltransferases.
The R1 peptide, GGFGGRGGFG-amide, derived from the
fibrillarin consensus methyl-acceptor site for PRMT enzymes,
FIG. 4. Amino acid analysis of peptide GGPGGRGGPGG-NH2
(R1) modified by GST-PRMT7 and purified by HPLC. A, peptide
R1 was methylated in vitro by GST-PRMT7, purified from contami-
nants by HPLC, and analyzed by amino acid analysis, as described
under “Experimental Procedures.” Controls were performed in the ab-
sence of GST-PRMT7 (B) and in the absence of the R1 peptide (C).
3H-radioactivity was determined by counting a 600-l aliquot of every
other fraction diluted with 400 l of water in 5 ml of fluor (Safety Solve,
Research Products International) three times for 3 min (). Unlabeled
amino acid standards (ADMA and -MMA) were analyzed using a
ninhydrin assay with 100-l aliquots of every other fraction (solid line).
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has been used to characterize protein-arginine N-methyltrans-
ferase activity present in cultured cells and in mammalian
tissues along with the activity of PRMT1 (11, 26). Even though
PRMT7 was unable to methylate the parent protein GST-GAR,
we decided to ask whether PRMT7 might be able to methylate
the consensus site in a peptide context. Reactions with peptide
R1 alone, peptide R1 plus GST-PRMT7, or GST-PRMT7 alone
were incubated with [3H]AdoMet. The R1 peptide was then
separated from other reaction components by C18 HPLC. 3H-
radioactivity was found to co-migrate with peptide R1 on the
C18 column in all three reaction mixtures (data not shown).
However, when the fractions corresponding to the peptide peak
were pooled in each case, acid-hydrolyzed, and then fraction-
ated by high-resolution amino acid analysis, we found radioac-
tivity to elute with the -NG-monomethylarginine derivative
only in the reaction containing GST-PRMT7 and peptide R1,
and not in the control reactions containing PRMT7 alone or
peptide alone (Fig. 4).
Because GST-PRMT7 is able to methylate a small peptide,
we decided to see whether PRMT7 could methylate free argi-
nine. We were intrigued by the presence of free -NG-monom-
ethylarginine and asymmetric -NG,NG-dimethylarginine in
mammals and their role as endogenous inhibitors of the nitric
oxide signaling pathway (27, 28). Free arginine (1 mM) was
incubated with GST-PRMT7 and [3H]AdoMet. Analysis of the
reaction by high-resolution cation exchange chromatography
did not reveal the presence of any 3H-methylated arginine
derivatives, suggesting that free arginine is not, in fact, a
substrate of PRMT7 (data not shown).
PRMT7 appears to have resulted from a gene duplication
event resulting in two PRMT domains (Fig. 5). The N-terminal
FIG. 5. PRMT7 contains two putative methyltransferase domains. A, a diagram of PRMT7 indicating the position of the two methyl-
transferase domains. The positions of the signature methyltransferase motifs (I, post I, II, and III) are displayed in black. B, the amino acid
sequence alignment of PRMT1 (splice variant 2) with PRMT7C and PRMT7N with conserved amino acid sequences in black boxes to highlight
the majority consensus. Signature seven -strand methyltransferase motifs I, post I, II, and III are indicated by boxes. The PRMT-conserved
glutamate residues of the “double E” loop are indicated by asterisks, and the PRMT-conserved THW loop is also boxed.
FIG. 6. Deletion of PRMT7 C-terminal or N-terminal domain
leads to a loss of methyltransferase activity. Peptide R1 (A) or
peptide R2 (B) were incubated with [3H]AdoMet and either GST-
PRMT7 (), GST-PRMT7C (amino acids 1–378, Œ), or GST-
PRMT7N (amino acids 379–992, f) as described under “Experimental
Procedures.” After reactions were dried and acid-hydrolyzed, methyl-
ated standards were added, and the hydrolysate was fractionated using
cation exchange chromatography, as described under “Experimental
Procedures.” 3H-radioactivity was determined by counting a 600-l
aliquot of every other fraction diluted with 400 l of water in 5 ml of
fluor three times for 3 min. The unlabeled amino acid standards were
analyzed using a ninhydrin assay with 100-l aliquots of every other
fraction.
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half of PRMT7 shown in Fig. 1 (amino acids 1–378) contains a
PRMT domain that is most similar to the catalytic core of
PRMT5, sharing 33% sequence identity, and is least similar to
PRMT2 and PRMT6 (21% identity). The C-terminal half of
PRMT7 (amino acids 379–692) shares 26% sequence identity
with PRMT1 and 22% sequence identity with the N-terminal
half of the protein (Fig. 5). The C-terminal half of PRMT7
shows less conservation in the AdoMet-binding motif I than the
N-terminal half and other PRMT enzymes, although it has an
identifiable THW loop. To determine whether the PRMT7 do-
mains can function independently, N-terminal and C-terminal
fusion proteins (GST-PRMT7C and GST-PRMT7N) were pu-
rified from E. coli and analyzed for peptidyl arginine methyl-
transferase activity. When either peptide R1 (Fig. 6A) or pep-
tide R2 (Fig. 6B) was used as a substrate, neither fusion protein
showed any methyltransferase activity, whereas the full-length
construct was able to catalyze the formation of -NG-monom-
ethylarginine in both peptides. UV crosslinking experiments
using [3H]AdoMet were also performed with GST-PRMT7C
and GST-PRMT7N. We found that GST-PRMT7C was able
to crosslink with [3H]AdoMet, whereas GST-PRMT7N was
not (data not shown). As seen with the full-length protein, the
addition of AdoMet, AdoHcy, and MTA inhibited the crosslink-
ing of [3H]AdoMet to GST-PRMT7, whereas the addition of
ATP had no effect.
In a recent study looking for genes that control the cell
response to cytotoxic agents, the Chinese hamster ortholog of
PRMT7 was identified as a gene corresponding to a genetic
suppressor element conferring resistance to a topoisomerase II
inhibitor (18). Immunoprecipitates of hemagglutinin-tagged
PRMT7 from the Chinese hamster cell line DC-3F cells were
shown to methylate MBP. Although the methylated product
was not identified in this study, it was assumed to be at an
arginine residue from the sequence similarities with other
PRMT enzymes (18). However, we show here that human GST-
PRMT7 purified from E. coli does not display any detectable
methyltransferase activity when MBP is used as a substrate.
Because the human and hamster proteins differ at 102 resi-
dues, it is possible that this difference is species-dependent.
However, it is hard to rule out the possibility that the activity
seen with the hamster enzyme preparation may be due to a
contaminating PRMT activity in the immunoprecipitated
PRMT7, or to the presence of additional subunits or regulatory
posttranslational modifications (12, 15).
In this work, we present direct evidence that GST-PRMT7 is
an arginine methyltransferase that can catalyze the formation
of -NG-monomethylarginine in peptides, although its physio-
logical substrate(s) have yet to be determined. The facts that
PRMT7 has an apparent duplication of methyltransferase do-
mains and is incapable of methylating the common PRMT
substrates GST-GAR, MBP, or histone H2A distinguishes it
from all other known arginine methyltransferases. It is not
clear whether PRMT7 may be a peptide-specific enzyme in vivo
or may be specific for yet unidentified substrates. It also re-
mains to be determined whether PRMT7 would be capable of
the addition of a second methyl group to an arginine residue in
an endogenous substrate to generate the asymmetric ADMA
residue of type I enzymes or the -NG,NG’-symmetric dimethy-
larginine residues of type II enzymes. It was previously sug-
gested that a crucial difference between enzymes that catalyze
type I versus type II methylation reactions is the size of the side
chain at the position corresponding to residue 163 in PRMT1
(15, 21). Here, the type I PRMT1, PRMT3, PRMT4, and PRMT6
enzymes contain a methionine residue, and the type II PRMT5
enzyme contains a serine residue; the latter may allow the
second methylation reaction to occur on the opposite guanidino
nitrogen atom. In the case of PRMT7, the residue here is an
alanine, suggesting the possibility of type II catalysis.
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